This inventor holds 2 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignee: Anaeropharma Science, Inc.. Active years: 2019-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2020
Title: Tomio Matsumura: Innovator in Bacterial Therapeutics
Introduction
Tomio Matsumura is a notable inventor based in Nagano, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of bacterial therapeutics. With a focus on enhancing therapeutic effects in anaerobic environments, his work has the potential to impact cancer treatment and ischemic diseases.
Latest Patents
Matsumura holds 2 patents that showcase his innovative approaches. His first patent involves a co-expression plasmid designed to provide an anaerobic enterobacterium with a higher therapeutic effect on solid tumor tissues and ischemic disease sites. This invention allows for the efficient secretion of two types of antibodies with anticancer effects outside the bacterial cell. His second patent focuses on a heterologous polypeptide expression cassette that enables the high-efficiency secretion of a scFv antibody with antitumor activity from a bacterium.
Career Highlights
Throughout his career, Matsumura has worked with various companies, including Anaeropharma Science, Inc. and Azusapharma Sciences, Inc. His expertise in biotechnology has allowed him to contribute to advancements in therapeutic applications using bacteria.
Collaborations
Matsumura has collaborated with notable individuals in his field, including Koichi Koseki and Koichiro Shioya. These collaborations have further enriched his research and development efforts.
Conclusion
Tomio Matsumura's innovative work in bacterial therapeutics highlights his commitment to advancing medical science. His patents reflect a deep understanding of biotechnology and its applications in treating serious health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile